EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis

Olga Morath, Jenny Rinke, Annabell Walter, Carl Crodel, Manja Meggendorfer, Constance Baer, Andreas Hochhaus, Thomas Ernst

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06361-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Olga Morath und 7 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. olga.morath@med.uni-jena.…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Thrombosis, Venous Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Jena.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While patients with myelofibrosis (MF) face an elevated risk of thrombosis, no validated scoring system currently exists to effectively assess this specific risk. This study aimed to explore distinct molecular risk factors for arterial (ATE) and venous (VTE) thrombosis in a cohort of 141 MF patients. Mutation analysis was performed by next-generation sequencing for a panel of 30 target myeloid genes as previously described: 137 driver and 164 non-driver mutations were detected. JAK2-V617F was identified in 77 (55%) patients, CALR in 45 (32%) patients, and seven (5%) patients carried an MPL variant. Patients #58 and #60 harbored JAK2-V617F and MPL ; and patient #67 was positive for all three driver genes. The JAK2 - V617F variant allele frequency (VAF) was assessed in 66/80 patients, revealing a median of 34.0% (range, 5.0–96.0). ASXL1 ( n = 34 patients) were the most common non-driver mutations, followed by TET2 ( n = 26), U2AF1 ( n = 12), and DNMT3A ( n = 11). During a median follow up of 4.8 years, 24 (17%) patients experienced VTE, 15 (11%) ATE, and two patients experienced both. Among the 24 patients with VTE, 12 (50%) experienced splanchnic vein thrombosis. The JAK2-V617F mutation was associated with VTE (OR 2.6, 95% CI 1.01–7.16), while the DNMT3A mutation was an independent predictor of ATE (OR 5.40, 95% CI 1.30-22.42). High JAK2-V617F VAF (> 50%) was not related with an increased thrombotic risk. Results of this study demonstrate the significance of DNMT3A mutations as an independent molecular risk factor for ATE, highlighting the potential to include these somatic non-driver mutations in future thrombosis risk scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisThrombosisVenous ThrombosisHumansMaleFemaleMiddle AgedAgedJanus Kinase 2AdultAged, 80 and overDNA Methyltransferase 3AMutationRisk FactorsDNA (Cytosine-5-)-MethyltransferasesReceptors, ThrombopoietinCalreticulinSplicing Factor U2AFRepressor ProteinsDioxygenasesDNA-Binding ProteinsCohort Studies

Stichwörter der Autor:innen

DNMT3AJAK2MyelofibrosisThrombosis

Substanzen

Janus Kinase 2JAK2 protein, humanDNA Methyltransferase 3ADNA (Cytosine-5-)-MethyltransferasesTET2 protein, humanDNMT3A protein, humanCALR protein, humanMPL protein, humanReceptors, ThrombopoietinASXL1 protein, human

Autor:innen und Institutionen

  • Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. olga.morath@med.uni-jena.de.
  • Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
  • MLL Münchner Leukämielabor GmbH, München, Germany.

Förderung

  • Universitätsklinikum Jena

Zitieren

APA

Morath, O., Rinke, J., Walter, A., Crodel, C., Meggendorfer, M., Baer, C., Hochhaus, A., & Ernst, T. (2025). Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06361-7

Vancouver

Morath O, Rinke J, Walter A, Crodel C, Meggendorfer M, Baer C, et al. Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06361-7

BibTeX
@article{Morath2025,
  author = {Morath, Olga and Rinke, Jenny and Walter, Annabell and Crodel, Carl and Meggendorfer, Manja and Baer, Constance and Hochhaus, Andreas and Ernst, Thomas},
  title = {Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06361-7}
}
Kostenlos starten →